NeuroPace (NASDAQ:NPCE) is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.
The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy. The system continuously records brain activity, detects abnormal electrical patterns that may lead to seizures, and delivers targeted stimulation to disrupt seizure activity before clinical symptoms arise. The RNS® System is implanted in the skull and connected directly to seizure foci via intracranial leads, offering a personalized therapy approach based on each patient’s unique seizure patterns.
NeuroPace holds regulatory approvals for the RNS® System in the United States and has obtained CE Mark certification for use in select European countries. The company works closely with leading epilepsy centers and neurosurgeons to support patient screening, surgical training, and postoperative programming. In addition to its clinical efforts, NeuroPace invests in ongoing research collaborations aimed at expanding closed-loop neuromodulation into other therapeutic areas, such as movement disorders and psychiatric conditions.
Guided by a leadership team with deep expertise in neurology, engineering and regulatory affairs, NeuroPace continues to refine its technology platform and explore new applications for responsive neurostimulation. The company maintains its headquarters in Silicon Valley and partners with hospitals, healthcare systems and academic institutions to enhance patient access and advance the scientific understanding of brain-responsive therapies.
